News headlines about Diffusion Pharmaceuticals (NASDAQ:DFFN) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diffusion Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.2715111524937 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Diffusion Pharmaceuticals traded down $0.03, reaching $0.53, during midday trading on Thursday, Marketbeat reports. 4,100 shares of the stock were exchanged, compared to its average volume of 652,221. The firm has a market capitalization of $28.30 million, a PE ratio of -0.46 and a beta of -1.06. Diffusion Pharmaceuticals has a 52 week low of $0.42 and a 52 week high of $3.04.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last posted its earnings results on Thursday, May 10th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.22). research analysts anticipate that Diffusion Pharmaceuticals will post -0.44 earnings per share for the current year.

A number of analysts recently weighed in on the stock. ValuEngine raised shares of Diffusion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. HC Wainwright assumed coverage on shares of Diffusion Pharmaceuticals in a report on Wednesday, March 21st. They set a “buy” rating and a $1.25 target price on the stock.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer.

Insider Buying and Selling by Quarter for Diffusion Pharmaceuticals (NASDAQ:DFFN)

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with's FREE daily email newsletter.